Sansure Biotech(SH:688289) Xin Lang Cai Jing·2025-09-02 00:43Core Viewpoint - The company reported a steady revenue growth in H1 2025, driven by strategic acquisitions and a focus on integrated diagnosis and treatment services [1][2] Group 1: Financial Performance - In H1 2025, the company achieved a revenue of 870 million yuan, representing a 21.2% increase year-on-year [1] - The net profit attributable to shareholders was 160 million yuan, up 3.8%, while the net profit excluding non-recurring items was 140 million yuan, reflecting a 12.2% growth [1] Group 2: Strategic Developments - The acquisition of Zhongshan Haiji in January 2025 allowed the company to enter the growth hormone sector, with Zhongshan Haiji generating 240 million yuan in revenue and 100 million yuan in net profit in H1 2025 [1] - The company’s high-throughput gene sequencing business saw revenue exceed 30 million yuan, tripling year-on-year, aided by the launch of the Sansure Seq1000 sequencer [1] - Investment in Shengweikunteng focuses on developing next-generation portable molecular POCT systems, enhancing the QPOC 2.0 platform with AI algorithms for improved diagnostic accuracy [1] - The company is expanding its routine business in respiratory diagnostics and leveraging the launch of domestic nine-valent HPV vaccines to create a synergistic service model in maternal and child health [1] Group 3: International Expansion - The company is transitioning its international strategy from traditional product output to ecological collaboration, with overseas revenue growing over 60% in H1 2025 [2] - In Europe, the company is increasing market penetration in private hospitals in France and Italy through a platform integration model [2] - In the ASEAN region, a training center in Jakarta is facilitating outreach to neighboring countries, while collaboration with Universiti Malaya focuses on tropical disease detection [2] - In Africa, a national cervical cancer HPV screening project in Sierra Leone has screened over 10,000 women and received a national public health contribution award [2] Group 4: Future Outlook - The company forecasts revenues of 2 billion yuan, 2.3 billion yuan, and 2.6 billion yuan for 2025, 2026, and 2027 respectively, with net profits projected at 310 million yuan, 360 million yuan, and 410 million yuan [2] - The integrated diagnosis and treatment layout is becoming increasingly comprehensive, suggesting a positive investment outlook [2]